Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $29.00 target price on the stock.

IMNN has been the subject of a number of other reports. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Imunon in a report on Wednesday, December 11th.

Imunon Stock Performance

Shares of IMNN stock opened at $0.83 on Thursday. Imunon has a 52-week low of $0.48 and a 52-week high of $3.65. The stock has a market cap of $12.04 million, a price-to-earnings ratio of -0.44 and a beta of 2.12. The firm’s 50-day moving average is $0.88 and its 200-day moving average is $1.08.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.